porcin
epidem
diarrhea
viru
pedv
member
genu
alphacoronaviru
famili
coronavirida
highli
contagi
caus
enter
diseas
pig
age
north
america
free
pedv
april
highli
virul
pedv
strain
classifi
non
indel
pedv
strain
suddenli
emerg
spread
quickli
throughout
unit
state
us
major
clinic
sign
porcin
epidem
diarrhea
ped
diarrhea
vomit
mortal
rate
high
neonat
piglet
born
pedv
sow
although
milder
clinic
sign
seen
older
pig
wean
pig
sow
growth
reproduct
perform
advers
impact
us
econom
impact
highest
includ
death
total
piglet
popul
billion
loss
subsequ
incid
new
pedv
case
show
season
pattern
peak
winter
suggest
epidem
pedv
outbreak
decreas
pedv
infect
may
mostli
endem
us
current
pedv
infect
occur
least
us
state
us
sow
herd
suffer
chronic
loss
http
wwwaasvorgresourcespedvpedvwhatsnewphp
effect
vaccin
program
requir
still
develop
well
document
natur
infect
andor
live
attenu
vaccin
elicit
local
mucos
immun
enter
viru
replic
intestin
mucosa
enter
virusinfect
recov
pregnant
sow
gutderiv
iga
immunocyt
b
memori
cell
migrat
mammari
gland
produc
high
titer
secretori
iga
siga
antibodi
ab
colostrum
milk
via
gutmammarysiga
axi
contribut
passiv
lactogen
immun
protect
neonat
suckl
piglet
diseas
sever
live
attenu
pedv
vaccin
base
classic
pedv
strain
use
asia
decad
howev
protect
emerg
highli
virul
pedv
strain
question
sever
ped
outbreak
occur
regularli
vaccin
farm
us
two
condit
licens
pedv
vaccin
base
emerg
highli
virul
pedv
strain
inactiv
vaccin
zoeti
parsippani
nj
alphavirusbas
pedv
subunit
vaccin
merck
ame
ia
howev
vaccin
pedv
giltssow
neither
vaccin
induc
high
protect
rate
ped
neonat
pig
one
possibl
reason
intramuscular
inject
inactiv
subunit
pedv
vaccin
mainli
stimul
system
mucos
immun
pedvspecif
immun
sow
recov
previou
pedv
infect
boost
vaccin
inactiv
vaccin
induc
suffici
level
lactogen
immun
protect
piglet
field
intent
infect
sow
autogen
pedv
gestat
feedback
exposur
use
induc
lactogen
immun
sow
protect
piglet
howev
feedback
exposur
risk
spread
infecti
agent
entir
herd
pedv
infect
may
becom
persist
farm
therefor
live
attenu
vaccin
base
emerg
highli
virul
pedv
strain
prime
mucos
immun
urgent
need
develop
us
laboratori
origin
us
highli
virul
pedv
strain
classifi
non
indel
strain
continu
passag
vero
cell
passag
passag
show
variou
degre
cell
cultur
adapt
vitro
virul
attenu
vivo
compar
highli
attenu
less
attenu
replic
effici
neonat
piglet
induc
higher
protect
rate
challeng
highli
virul
homolog
viru
well
document
wean
pig
sow
less
suscept
pedv
infect
neonat
piglet
mani
highli
attenu
pedv
porcin
transmiss
gastroenter
viru
tgev
strain
replic
poorli
induc
margin
immun
wean
pig
sow
evalu
vaccin
candid
sow
expens
laborintens
young
pig
wean
pig
use
surrog
model
initi
evalu
safeti
immun
respons
protect
efficaci
pedv
vaccin
candid
therefor
aim
studi
character
pathogen
immunogen
two
pedv
vaccin
candid
pedv
strain
wean
pig
six
pig
inocul
diarrhea
fecal
consist
fc
score
dpi
one
pig
wateri
diarrhea
fc
score
one
day
dpi
diarrhea
last
day
ceas
individu
pig
dpi
fig
addit
pig
gain
weight
kg
first
week
tabl
howev
growth
retard
last
dpi
convers
pig
group
clinic
sign
except
transient
mild
diarrheasoft
fece
observ
pig
around
dpi
fecal
pedv
rna
shed
around
detect
limit
undetect
firstweek
bodi
weight
gain
profil
postinocul
similar
among
pig
mock
group
fecal
pedv
rna
detect
pig
mock
group
fig
group
pig
shed
mediumhigh
pedv
rna
amount
copiesml
fece
earli
dpi
mean
titer
peak
copiesml
dpi
drop
mean
dpi
copiesml
dpi
afterward
mean
titer
peak
copiesml
dpi
decreas
gradual
ceas
dpi
dpi
among
pig
four
six
pig
group
began
shed
fecal
pedv
rna
dpi
mean
titer
copiesml
also
peak
mean
viral
rna
titer
pig
howev
fecal
viral
rna
shed
delay
fifth
pig
dpi
detect
sixth
pig
dpi
individu
pig
group
low
fecal
pedv
rna
titer
copiesml
stop
shed
dpi
pig
group
shed
fecal
pedv
rna
mean
titer
peak
copiesml
dpi
stop
shed
dpi
dynam
serum
pedvspecif
iga
igg
ab
respons
post
inocul
among
pig
similar
appear
pig
dpi
peak
dpi
decreas
dpi
fig
serum
igg
ab
titer
gener
higher
iga
ab
titer
time
point
dpi
five
two
six
pig
detect
serum
pedv
iga
igg
ab
titer
respect
pig
develop
pedv
iga
igg
ab
titer
serum
dpi
fig
b
serum
pedv
viral
neutral
vn
ab
first
detect
dpi
titer
decreas
dpi
fig
except
one
pig
fecal
viral
rna
shed
pedv
ab
respons
serum
iga
igg
vn
ab
titer
group
similar
group
dpi
pig
low
titer
iga
igg
vn
ab
inocul
pedvspecif
ab
detect
serum
collect
pig
mock
group
none
pig
studi
detect
serum
pedvspecif
igm
ab
challeng
pig
group
clinic
sign
fig
transient
low
intermedi
level
fecal
pedv
rna
shed
copiesml
fig
hand
pig
mock
group
acut
onset
sever
diarrhea
fc
high
fecal
pedv
rna
shed
titer
cumul
fc
score
dpc
mock
group
similar
significantli
higher
group
p
tabl
fecal
pedv
rna
shed
titer
mock
group
peak
similar
high
level
dpi
subsequ
fecal
pedv
rna
shed
titer
group
decreas
faster
mock
group
fig
mean
durat
fecal
pedv
rna
shed
day
post
challeng
group
howev
pig
mock
group
continu
shed
pedv
rna
fece
end
studi
challeng
pig
mock
group
lost
weight
tabl
wherea
pig
group
similar
bodi
weight
gain
profil
group
serum
pedv
iga
igg
vn
ab
titer
group
pig
increas
challeng
fig
highest
secondari
ab
respons
observ
pig
group
whose
serum
pedv
ab
titer
significantli
higher
three
group
p
dpi
fig
hand
serum
pedv
iga
igg
ab
titer
pig
mock
group
similar
except
pig
mock
group
significantli
higher
serum
pedv
iga
ab
titer
group
p
fig
interestingli
foldincreas
pedv
ab
group
iga
igg
vn
lower
mock
group
iga
igg
vn
group
iga
igg
vn
consist
lower
iga
igg
vn
group
challeng
fig
investig
intestin
ab
secretori
cell
respons
two
four
pig
group
euthan
challeng
dpi
challeng
dpc
dpi
respect
challeng
pedvspecif
iga
absecret
cell
asc
detect
pig
low
level
dpc
dpi
group
significantli
higher
number
iga
asc
mesenter
lymph
node
mln
ileum
rang
per
msc
mock
group
asc
per
msc
p
fig
raw
data
provid
addit
file
live
attenu
pedv
vaccin
replic
gut
provid
suffici
stimul
elicit
protect
mucos
immun
caus
neglig
clinic
sign
howev
requir
usual
mutual
exclus
attenu
vaccin
develop
use
tradit
cell
cultur
method
alon
previou
studi
report
pig
oral
oronas
inocul
attenu
pedv
tegv
rotaviru
strain
develop
lower
protect
immun
pig
infect
correspond
virul
viru
tgev
naiv
sow
oral
inocul
virul
tgev
multi
dose
attenu
tgev
vaccin
induc
passiv
protect
nurs
pig
studi
pig
inocul
virul
pedv
develop
complet
protect
immun
subsequ
challeng
high
dose
homolog
viru
although
one
pig
group
diarrhea
fc
dpi
fecal
pedv
rna
shed
extrem
low
copiesml
dpi
undetect
dpi
diarrhea
probabl
attribut
infect
neither
attenu
caus
diseas
wean
pig
fulfil
safeti
requir
vaccin
hand
one
dose
induc
suffici
immun
protect
pig
diarrhea
post
challeng
optim
stimul
mucos
immun
respons
requir
local
viru
replic
adequ
amount
viral
antigen
present
suffici
period
time
abil
viru
replic
intestin
epitheli
cell
dose
viru
inoculum
two
critic
factor
short
durat
fecal
pedv
rna
shed
indic
replic
limit
extent
wean
pig
inoculum
dose
plaqu
format
unit
pfu
per
pig
use
virus
similar
copiesml
correspond
pfu
virul
pedv
strain
isol
pedv
outbreak
strain
whether
higher
dose
current
pfu
per
pig
andor
multipl
dose
would
enhanc
protect
effici
examin
futur
previou
studi
confirm
partial
attenu
neonat
pig
piglet
milder
villou
atrophi
delay
onset
shorten
durat
fecal
pedv
rna
shed
compar
piglet
furthermor
attenu
base
longer
incub
time
lower
fecal
viru
shed
titer
limit
viral
antigen
distribut
intestin
studi
still
virul
complet
attenu
wean
pig
probabl
due
agedepend
resist
diseas
wean
versu
neonat
piglet
show
substanti
differ
pathogen
neither
caus
clinic
sign
wean
pig
besid
one
six
pig
group
product
infect
establish
suggest
hostrel
variabl
suscept
pedv
probabl
contribut
result
howev
three
virus
differ
significantli
immunogen
group
group
titer
serum
pedv
iga
igg
vn
ab
number
pedv
iga
asc
boost
significantli
challeng
addit
fecal
pedv
rna
shed
titer
group
decreas
earlier
mock
group
post
challeng
result
suggest
infect
induc
stronger
primari
anamnest
immun
respons
howev
pig
lower
serum
pedv
ab
titer
inocul
post
inocul
challeng
anamnest
immun
respons
group
margin
interestingli
serum
secondari
ab
respons
group
lower
group
although
number
ileum
iga
asc
significantli
higher
group
group
intestin
iga
ab
gener
consid
relev
protect
pedv
infect
like
pig
inocul
virul
develop
suffici
intestin
mucos
immun
respons
effici
neutral
challeng
viru
prevent
viru
replic
correspond
low
fecal
pedv
rna
shed
diseas
hand
even
attenu
elicit
iga
igg
ab
respons
dpi
provid
wean
pig
suffici
mucos
protect
virul
challeng
replic
challeng
viru
pig
group
induc
higher
serum
secondari
immun
respons
group
two
previou
studi
compar
immun
respons
induc
virul
attenu
pedv
convent
pig
respect
gener
virul
pedv
provid
higher
level
protect
immun
attenu
strain
none
virul
pedvinocul
pig
develop
clinic
sign
challeng
homolog
viru
howev
differ
attenu
virus
induc
variou
protect
rate
studi
attenu
pedv
strain
pig
high
dose
group
fluoresc
focu
format
unit
ffu
pig
low
dose
group
ffupig
mock
group
respect
develop
diarrhea
virul
challeng
unknown
dose
dpi
studi
attenu
pedv
pt
strain
mockinocul
pig
develop
wateri
diarrhea
challeng
virul
pedv
wk
post
inocul
none
attenu
pedv
pig
develop
diarrhea
challeng
studi
pig
mock
group
show
diarrhea
challeng
viru
pfupig
dpi
overal
differ
viru
strain
pig
condit
age
sourc
pig
breed
etc
use
differ
laboratori
may
contribut
variabl
protect
rate
addit
investig
pedvspecif
cellular
immun
respons
may
play
import
role
protect
pedv
challeng
studi
cell
immun
respons
pedv
infect
futur
provid
complet
pictur
protect
immun
better
guidanc
pedv
vaccin
develop
longterm
goal
studi
develop
safe
efficaci
live
attenu
vaccin
target
sow
gener
lactogen
immun
protect
neonat
piglet
ped
studi
convent
wean
pig
use
evalu
safeti
effici
vaccin
candid
three
reason
previou
studi
suggest
young
pig
use
surrog
model
evalu
potenti
sow
vaccin
econom
compar
use
sow
evalu
safeti
immunogen
vaccin
candid
wean
pig
potenti
target
vaccin
activ
immun
agaist
ped
two
partial
attenu
pedv
vaccin
candid
replic
lower
extent
viru
caus
diseas
wean
pig
howev
concern
remain
attenu
pedv
strain
may
revert
virul
via
mutat
natur
host
gener
new
virul
strain
exchang
gene
field
strain
via
recombin
develop
revers
genet
technolog
viru
limit
replic
compet
defect
recombin
engin
allevi
concern
futur
hand
induc
insuffici
immun
respons
protect
pig
challeng
high
dose
virul
viru
challeng
inocul
pig
develop
strong
anamnest
ab
respons
consid
fact
feedback
method
use
highli
virul
pedv
virus
may
facilit
spread
infecti
agent
herd
pedv
persist
farm
inactivatedsubunit
pedv
vaccin
mainli
effect
previous
pedvexpos
pedvnaiv
sow
safe
efficaci
live
attenu
pedv
vaccin
still
urgent
need
howev
result
demonstr
difficulti
challeng
develop
live
attenu
vaccin
use
cell
cultur
adapt
method
alon
avail
infecti
clone
system
pedv
modifi
enhanc
immunogen
maintain
attenu
combin
attenu
inactiv
vaccin
andor
inclus
mucos
adjuv
may
safe
effect
pedv
vaccin
regimen
confirm
tgev
sow
vaccin
hypothes
investig
futur
vero
cell
adapt
pedv
fulli
attenu
wean
pig
fail
provid
protect
diarrhea
caus
challeng
highli
virul
result
demonstr
difficulti
obtain
fulli
attenu
pedv
retain
immunogen
use
tradit
cell
cultur
adapt
approach
therefor
understand
molecular
mechan
pedv
attenu
ration
design
vaccin
use
revers
genet
technolog
direct
develop
safe
efficaci
attenu
vaccin
pedv
isol
continu
passag
pedv
strain
vero
cell
report
previous
third
passag
use
virul
inoculum
posit
control
homolog
challeng
pool
pathogen
confirm
highli
virul
three
pfu
caus
sever
diarrhea
mortal
cesareanderiv
colostrumdepriv
cdcd
piglet
two
highlevel
passag
select
attenu
vaccin
candid
plaquepurifi
clone
use
studi
caus
moder
diarrhea
cdcd
piglet
without
mortal
detail
inform
regard
viru
growth
kinet
cell
cultur
virul
neonat
pig
whole
genom
sequenc
analysi
report
previous
twentyfour
convent
wean
pig
day
age
purchas
ohio
state
univers
osu
specif
pathogenfre
spf
herd
histori
pedv
tgev
porcin
reproduct
respiratori
syndrom
viru
prrsv
outbreak
nasal
rectal
swab
collect
pig
confirm
neg
pedv
tgevporcin
respiratori
coronaviru
prcv
porcin
delta
coronaviru
porcin
group
group
c
rotavirus
describ
previous
convent
rtpcr
reveal
weak
posit
group
porcin
rotaviru
data
shown
day
acclim
biosafeti
level
facil
day
age
pig
diarrhea
rectal
swab
sampl
neg
rotaviru
rna
rtpcr
twentyfour
wean
pig
randomli
divid
four
group
six
pigsgroup
initi
mean
bodi
weight
pig
group
similar
group
pig
hous
separ
room
oral
inocul
pfu
pfu
pfu
virusfre
medium
mock
infect
respect
tabl
oral
inoculum
dose
base
previou
data
nucleocapsid
n
gene
copi
viral
rna
correspond
approxim
pfu
highli
virul
us
pedv
strain
requir
infect
convent
pig
inocul
piglet
observ
twice
daili
clinic
sign
includ
vomit
diarrhea
anorexia
rectal
swab
collect
daili
first
dpi
everi
day
thereaft
fecal
consist
fc
score
follow
solid
pasti
semiliquid
liquid
respect
fecal
consist
score
consid
diarrhea
fecal
pedv
rna
shed
detect
taqman
realtim
revers
transcriptionpcr
rtqpcr
assay
bodi
weight
measur
blood
sampl
obtain
inocul
weekli
postinocul
dpi
pig
per
group
randomli
select
euthan
examin
system
intestin
iga
asc
dpi
pig
oral
challeng
virul
viru
consid
clinic
sign
pig
fact
challeng
done
older
pig
dpi
dose
use
challeng
increas
pfupig
higher
pfupig
use
initi
inocul
pig
group
fc
score
record
day
pig
diarrhea
studi
termin
day
postchalleng
dpc
pig
euthan
blood
tissu
collect
pig
euthan
tkx
combo
ml
xylazin
mgml
ml
ketamin
mgml
telazol
tiletamin
mgml
zolazemin
mgml
dose
mlkg
weight
intramuscular
inject
follow
electrocut
exsanguin
rs
sampl
suspend
minimum
essenti
media
invitrogen
carlsbad
ca
usa
fecal
suspens
rna
extract
use
viral
isol
kit
ambion
austin
tx
usa
subject
rtqpcr
primer
probe
target
pedv
n
gene
detect
limit
n
gene
copi
per
reaction
correspond
copi
per
ml
origin
fecal
sampl
monolay
vero
cell
wellplat
inocul
overnight
fix
acetonemethanol
min
serial
dilut
pig
serum
sampl
pb
prepar
fiftymicrolit
sampl
dilut
ad
well
plate
incub
room
temperatur
h
rins
twice
pb
min
fluorescein
isothiocyan
fitc
conjug
goat
antiswin
igg
kpl
west
chester
pa
goat
antiswin
iga
biorad
hercul
ca
dilut
ad
h
incub
dark
plate
rins
twice
pb
min
time
examin
use
fluoresc
microscop
olympu
center
valley
pa
test
one
posit
antiserum
known
pedv
ab
titer
one
neg
pig
serum
includ
posit
neg
control
respect
sampl
test
least
triplic
ab
titer
express
mean
repeat
calcul
base
transform
detail
procedur
ffrvn
describ
previous
briefli
pig
serum
sampl
inactiv
follow
serial
dilut
pb
dilut
mix
equal
volum
pedv
stock
contain
fluoresc
focu
unit
ffu
h
incub
serumviru
mixtur
inocul
onto
confluent
vero
cell
monolay
enhanc
viru
absorpt
brief
centrifug
min
conduct
subsequ
inoculum
remov
replac
dmem
supplement
trypsin
h
incub
dmem
supplement
fb
ad
block
action
trypsin
plate
incub
overnight
cell
cultur
immunofluoresc
assay
ccif
procedur
conduct
use
pedv
n
monoclon
ab
fitcconjug
goat
antimous
igg
serotec
primari
secondari
antibodi
respect
number
ffu
well
count
vn
ab
titer
serum
sampl
express
reciproc
dilut
give
reduct
number
ffu
sera
test
triplic
final
ab
titer
express
mean
repeat
mnc
spleen
mln
ileum
blood
isol
follow
routin
procedur
laboratori
fragment
ileum
wash
twice
first
wash
solut
rpmi
mm
hepe
acid
mg
gentamicin
per
ml
mg
ampicillin
per
ml
follow
hank
balanc
salt
solut
tissu
cut
small
piec
place
hbss
contain
mm
dithiothreitol
mm
edta
vigor
shaken
min
dislodg
epitheli
cell
subsequ
segment
minc
suspend
rpmi
contain
fetal
bovin
serum
u
type
ii
collagenas
sigma
chemic
co
st
loui
mo
per
ml
digest
min
gentl
shake
afterward
supernat
collect
remain
tissu
press
stainless
steel
collector
fit
mesh
screen
collector
fl
usa
similarli
spleen
mln
also
minc
press
stainless
steel
screen
singl
cellular
suspens
collect
subject
gradient
centrifug
percol
sigma
blood
collect
asept
vv
acid
citrat
glucos
peripher
blood
lymphocyt
isol
ficollpaqu
ficollpaqu
research
grade
pharmacia
biotech
uppsala
sweden
densiti
gradient
centrifug
collect
mnc
subject
frozen
liquid
nitrogen
describ
confluent
vero
cell
monolay
plate
inocul
pedv
moi
hpi
cell
infect
pedv
test
ccif
cell
monolay
still
intact
plate
fix
aceton
min
airdri
store
use
day
assay
mnc
quickli
thaw
liquid
nitrogen
first
resuspend
cold
epmi
follow
centrifug
remov
dmso
freez
medium
cell
resuspend
epmi
incub
h
plate
thaw
rehydr
incub
pb
room
temperatur
differ
amount
live
mnc
tissu
ad
duplic
well
plate
centrifug
x
g
min
incub
h
subsequ
plate
wash
pb
contain
tween
pbst
ab
product
detect
use
horseradish
peroxidaselabel
affinitypurifi
goat
antipig
iga
antibodi
kpl
maryland
dilut
pbst
incub
h
rt
final
spot
develop
tetramethylbenzidin
tmb
membran
peroxidas
substrat
system
kpl
count
averag
duplic
well
data
express
mean
number
asc
per
mnc
analysi
varianc
anova
follow
duncan
multiplerang
test
use
demonstr
statist
differ
viru
sheddingab
titer
number
asc
among
four
pig
group
fc
score
compar
use
kruskalw
nonparametr
analysi
compar
bodi
weight
gain
among
group
analysi
covari
ancova
appli
adjust
initi
bodi
weight
comparison
piglet
serum
ab
titer
time
point
conduct
use
pair
ttest
statist
analys
done
use
sa
statist
analysi
system
sa
window
sa
institut
inc
cari
nc
usa
p
valu
consid
signific
